Selinexor and Venetoclax Combination in Patients With Relapsed or Refractory Acute Myeloid Leukemia.

Saved in:
Bibliographic Details
Title: Selinexor and Venetoclax Combination in Patients With Relapsed or Refractory Acute Myeloid Leukemia.
Authors: Ball S; Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA.; Division of Hematology and Oncology, Department of Internal Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA., Awan FT; Division of Hematology and Oncology, University of Texas Southwestern Medical Center, Dallas, Texas, USA., Tomlinson BK; Department of Hematology and Stem Cell Transplant, University Hospitals Seidman Cancer Center, Cleveland, Ohio, USA., Stopczynski T; Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, Tennessee, USA., Fischer MA; Division of Hematology and Oncology, Department of Internal Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA., Zhao Z; Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, Tennessee, USA., Fedorov K; Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA.; Division of Hematology and Oncology, Department of Internal Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA., Kishtagari A; Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA.; Division of Hematology and Oncology, Department of Internal Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA., Mohan SR; Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA.; Division of Hematology and Oncology, Department of Internal Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA., Ayers GD; Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, Tennessee, USA., Byrne MT; Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA.; Division of Hematology and Oncology, Department of Internal Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.; Tennessee Oncology, Nashville, Tennessee, USA., Savona MR; Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA.; Division of Hematology and Oncology, Department of Internal Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.; Program in Cancer Biology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
Source: American journal of hematology [Am J Hematol] 2026 May; Vol. 101 (5), pp. 1019-1024. Date of Electronic Publication: 2026 Mar 08.
Publication Type: Journal Article; Clinical Trial, Phase I
Journal Info: Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 7610369 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1096-8652 (Electronic) Linking ISSN: 03618609 NLM ISO Abbreviation: Am J Hematol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1096-8652
DOI:10.1002/ajh.70266